Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report

Pediatric Blood and Cancer

Volumn 64, Issue 3, 2017, Pages

  Shad, Aziza T ^a,c   Huo, Jeffrey S ^b   Darcy, Courtney ^c   Abu Ghosh, Amal ^c   Esposito, Giuseppe ^c   Holuba, Mary Jo ^b   Robey, Nancy ^b   Cooke, Kenneth R ^b   Symons, Heather J ^b   Chen, Allen R ^b   Llosa, Nicolas J ^b  

^a The Herman & Walter Samuelson Children's Hospital at Sinai   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

anti PD1; haploidentical bone marrow transplant; Hodgkin lymphoma; immunotherapy; nivolumab; relapse

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; MESNA; METHOTREXATE; MYCOPHENOLATE MOFETIL; NIVOLUMAB; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RAPAMYCIN; TACROLIMUS; VINBLASTINE; VINCRISTINE; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLASSICAL HODGKIN LYMPHOMA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBRINOLYTIC THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; NONMYELOABLATIVE CONDITIONING; PANCREATIC INSUFFICIENCY; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; WHOLE BODY RADIATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; DRUG EFFECTS; GRAFT VS HOST DISEASE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE DEPLETION; PROGNOSIS; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; FEMALE; GRAFT VS HOST DISEASE; HODGKIN DISEASE; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE DEPLETION; PROGNOSIS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84988412553     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.26257     Document Type: Article

References (13)

1. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10–24.
2. McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125(19):3024–3031.
3. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–288.
4. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
5. Saha A, Aoyama K, Taylor PA, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood. 2013;122(17):3062–3073.
6. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171(3):1272–1277.
7. Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol. 2014;32(32):3651–3658.
8. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111(1):109–111.
9. Janku F, Oki Y, Falchook GS, et al. Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients. J Clin Oncol (ASCO Annu Meet Abstr). 2014;32(15 Suppl):8508.
10. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311–319.
11. Angenendt L, Schliemann C, Lutz M, et al. Nivolumab in a patient with refractory Hodgkin's lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;51:443–445.
12. Herbaux C, Morshhauser MD. Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin's lymphoma after allogeneic hematopoietic cell transplantation: a study from the Lysa and SFGM-TC. Blood. 2015;126(23):3979.
13. Yared JA, Hardy N, Singh Z, et al. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(6):850–852.